A Phase III, Double Blind, Randomized Study to Evaluate Safety and Efficacy of BAL8557 Versus Voriconazole for Primary Treatment of Invasive Fungal Disease Caused byAspergillus Species or Other Filamentous Fungi
|Effective start/end date||6/13/11 → 12/31/14|
- Astellas Pharma US, Inc.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.